Q-omics provides the consensus-scored OPALIN profile across patient tissues and cancer cell-line models. OPALIN expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OPALIN is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, OPALIN RNA expression shows 12,977 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where OPALIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OPALIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OPALIN survival associations across molecular data types. OPALIN RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OPALIN RNA expression–survival associations across cancer types. High OPALIN expression shows unfavorable associations in ACC, MESO, READ, KIRC and PCPG, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for OPALIN RNA expression.
This table summarizes OPALIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OPALIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OPALIN shows lower tumor expression in THCA and higher tumor expression in KICH, HNSC, LUSC and LUAD. The THCA box plot shows higher OPALIN RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p < 0.001).
This table shows molecular features associated with OPALIN in patient tissues and cancer cell lines. In patient samples, OPALIN shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OPALIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
